Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel

Cancer

Volumn 95, Issue 6, 2002, Pages 1265-1273

  Socinski, Mark A ^a   Schell, Michael J ^a   Bakri, Kamal ^a   Peterman, Amy ^b   Lee, Ji Hyun ^a   Unger, Paul ^c   Yates, Steven ^a   Hudgens, Stacie ^b   Kies, Merrill S ^d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Max Nader Center for Rehab Technologies and Outcomes Research   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carboplatin; Chemotherapy; Lung carcinoma; Nonsmall cell lung carcinoma; Paclitaxel; Second line treatment

Indexed keywords

CARBOPLATIN; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; DRUG RESPONSE; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NEUROPATHY; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037105519     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10835     Document Type: Article

References (25)

1. Cancer statistics, 2001
2. Non-small cell lung cancer. Part I: Biology, diagnosis, and staging
3. New Chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
4. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
5. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing regimens
6. Quality of life (QoL) assessment in randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinum-based chemotherapy
7. Docetaxel (D) benefits lung cancer symptoms and quality of life (QoL) in a randomized phase III study of non-small cell lung cancer (NSCLC) patients previously treated with platinum-based therapy
8. Patterns of practice survey for non-small cell lung cancer in the U.S.
9. Interim analysis of a Phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer
10. Weekly paclitaxel in advanced non-small cell lung cancer
11. Reinduction of response with weekly taxol (T) in advanced breast cancer (ABC)
12. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
13. A Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced Stage IIIB/IV non-small cell lung cancer
14. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument
15. Optimal two-stage designs for phase II clinical trials
16. Combined modality therapy in the non-surgical management of unresectable Stage III non-small cell lung cancer
17. Phase II study of taxol in patients with non-small cell lung cancer who have failed platinum containing chemotherapy
18. Second-line chemotherapy for resistant metastatic non-small cell lung cancer: The role of taxol
19. Taxol is active as a 3-hour or 24-hour infusion non-small cell lung cancer
20. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small cell lung cancer
21. Paclitaxel (Taxol®) as a single agent salvage therapy in non-small cell lung cancer (NSCLC)
22. Second-line chemotherapy with 96-hour infusion paclitaxel in refractory non-small cell lung cancer. Report of a phase II trial
23. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: A phase II trial
24. Second-line gemcitabine in refractory Stage IV non-small cell lung cancer: A phase II trial